SBIO ALPS Medical Breakthroughs ETF
Quote as of Oct 09, 2026 19:59 UTC · Market data delayed approximately 15–20 minutes unless otherwise indicated.
| Previous Close | 53.95 | Day Range | 54.38 – 55.51 |
| 52-Week Range | 40.57 – 70.85 | Volume | 33.63K |
| Avg Volume | 41.79K | AUM | $187.5M (Oct 10, 2026) |
| Expense Ratio | 0.50% | Yield (TTM) | — |
| NAV | 53.95 | Premium/Discount | +2.02% indicative |
| Inception | Dec 30, 2014 | Holdings | 103 |
| Issuer | ALPS Funds | Exchange | AMEX |
| Category | Biotech | Index Tracked | Not stated in source data |
| CUSIP | 00162Q593 | ISIN | US00162Q5936 |
| Management | Passive / index-tracking (per issuer description) | ||
About this ETF
The fund employs a "passive management" - or indexing - investment approach designed to track the performance of the underlying index. It will normally invest at least 80% of its net assets in securities that comprise the underlying index. The underlying index is comprised of small and mid-cap stocks of biotechnology companies that have one or more drugs in either Phase II or Phase III of the U.S. Food and Drug Administration clinical trials.
Description from the fund data provider · profile as of Oct 10, 2026.
Price Chart
Daily closing prices (price return, not total return). Comparison lines are normalized to percent change from the range start. Source: Financial Modeling Prep.
Performance
| 1M | 3M | 6M | YTD | 1Y | 3Y* | 5Y* | 10Y* | Incep.* | |
|---|---|---|---|---|---|---|---|---|---|
| Price return | -15.58% | -18.12% | +1.96% | +7.46% | +32.63% | +27.58% | +3.86% | +8.14% | +6.99% |
| Total return | -15.58% | -18.12% | +1.96% | +7.46% | +32.63% | +29.17% | +4.63% | +9.03% | +7.75% |
* Annualized. Total return uses the dividend-adjusted price series (distributions reinvested); price return uses unadjusted closes. Performance through Oct 09, 2026. Past performance does not guarantee future results.
Fees
| Net expense ratio | 0.50% | Annual cost of a $10,000 investment | $50.00 |
Illustrative calculation only: expense ratio × $10,000. It excludes trading costs, bid/ask spreads, taxes and changes in investment value. Gross vs. net expense details and any fee waivers are in the prospectus.
Holdings
Holdings as of Oct 10, 2026 · portfolio reporting date from the data provider; holdings are not live positions. 104 rows in database.
| # | Holding | Ticker | Weight | Shares | Market Value |
|---|---|---|---|---|---|
| 1 | CG oncology Inc. | CGON | 3.76% | 112.60K | $7.2M |
| 2 | VeraDermics Inc. | MANE | 3.63% | 53.06K | $6.9M |
| 3 | Oruka Therapeutics Inc. | ORKA | 3.61% | 84.11K | $6.9M |
| 4 | Definium Therapeutics Inc. | DFTX | 3.29% | 170.64K | $6.3M |
| 5 | Travere Therapeutics Inc. | TVTX | 3.26% | 119.73K | $6.2M |
| 6 | Dianthus Therapeutics Inc. | DNTH | 3.06% | 71.02K | $5.8M |
| 7 | Edgewise Therapeutics Inc. | EWTX | 2.81% | 137.91K | $5.4M |
| 8 | Relay Therapeutics Inc. | RLAY | 2.60% | 278.31K | $5.0M |
| 9 | Amylyx Pharmaceuticals Inc. | AMLX | 2.34% | 159.43K | $4.5M |
| 10 | Xenon Pharmaceuticals Inc. | XENE | 2.34% | 122.98K | $4.5M |
| 11 | Ideaya Biosciences Inc. | IDYA | 2.31% | 122.54K | $4.4M |
| 12 | ACADIA Pharmaceuticals Inc. | ACAD | 2.26% | 218.86K | $4.3M |
| 13 | Tarsus Pharmaceuticals Inc. | TARS | 2.13% | 55.72K | $4.1M |
| 14 | Denali Therapeutics Inc. | DNLI | 2.06% | 203.01K | $3.9M |
| 15 | Dyne Therapeutics Inc. | DYN | 2.06% | 237.17K | $3.9M |
| 16 | Zai Lab Ltd. | ZLAB | 1.87% | 142.83K | $3.6M |
| 17 | Newamsterdam Pharma Co. NV | NAMS | 1.71% | 151.85K | $3.3M |
| 18 | MBX Biosciences Inc. | MBX | 1.70% | 61.16K | $3.3M |
| 19 | Disc Medicine Inc. | IRON | 1.58% | 48.75K | $3.0M |
| 20 | SELLAS Life Sciences Group Inc. | SLS | 1.56% | 256.48K | $3.0M |
| 21 | Celldex Therapeutics Inc. | CLDX | 1.56% | 99.75K | $3.0M |
| 22 | Immunome Inc. | IMNM | 1.47% | 144.28K | $2.8M |
| 23 | BioCryst Pharmaceuticals Inc. | BCRX | 1.45% | 324.54K | $2.8M |
| 24 | Vera Therapeutics Inc. | VERA | 1.43% | 91.55K | $2.7M |
| 25 | Viridian Therapeutics Inc. | VRDN | 1.40% | 143.87K | $2.7M |
Click a ticker to see every ETF that owns it.
Sector Exposure
Geographic Exposure
Country weights as reported by the data provider. Developed/emerging/frontier labels follow the classification on the Methodology page. Currency hedged: No hedging indicated in the fund name.
Distributions
| Yield (TTM) | — | Paid (last 12 months) | — |
| Frequency | Annual | SEC yield | Not provided by our data source; see the issuer page |
| Last ex-date | Dec 19, 2024 | Last payment | $1.1735 (Dec 26, 2024) |
| Growth 1Y | — | Growth 3Y / 5Y (ann.) | — / — |
| Ex-date | Record | Pay date | Amount |
|---|---|---|---|
| Dec 19, 2024 | Dec 19, 2024 | Dec 26, 2024 | $1.1735 |
| Dec 21, 2023 | Dec 22, 2023 | Dec 27, 2023 | $0.0711 |
| Dec 19, 2019 | Dec 20, 2019 | Dec 27, 2019 | $0.0160 |
| Dec 20, 2018 | Dec 21, 2018 | Dec 27, 2018 | $0.7840 |
| Dec 21, 2017 | Dec 22, 2017 | Dec 28, 2017 | $0.5790 |
Trailing distribution yield = last 12 months of cash ÷ current price. It is NOT the SEC 30-day yield and distributions are not guaranteed to continue. The difference explained →
Risk Statistics
| Volatility 1Y / 3Y | 31.57% / 31.30% | Sharpe 1Y / 3Y | 1.12 / 1.01 |
| Max drawdown 1Y / 3Y | -23.79% / -42.44% | Sortino 1Y | 1.72 |
| Beta vs S&P 500 (3Y) | 1.04 | Correlation vs S&P 500 (1Y) | 0.407 |
| Downside deviation 1Y | 20.55% | Risk-free rate used | 4.05% (3M T-bill, FRED) |
Computed by ETF Explorer from daily dividend-adjusted closes; volatility and drawdown are annualized/period figures; S&P 500 exposure proxied by SPY. As of Oct 10, 2026. Formulas →
Liquidity
| Volume today | 33.63K | Average volume | 41.79K |
| AUM | $187.5M | Premium/Discount | +2.02% |
| Bid/Ask spread | Not provided by our data source. Check your broker's quote screen; spreads are widest at the open and close. | ||
Premium/discount compares the delayed market price with the last reported NAV: an indicative figure, not the official closing premium/discount. How ETF liquidity works →
Fund Flows (estimated)
| Period | Est. net flow | % of starting AUM | AUM start → end |
|---|---|---|---|
| 1 Day | -$795.8K | -0.42% | $188.3M → $187.5M |
| 1 Month | -$24.2M | -9.85% | $245.3M → $187.5M |
| 1 Week | -$14.3M | -6.93% | $205.8M → $187.5M |
ETF Explorer estimate: change in reported AUM minus the market-move effect, from our own daily snapshots. Not official issuer creation/redemption data.
Official Fund Resources
External links open the issuer's site or SEC EDGAR in a new tab. The prospectus and official documents are always the authoritative source; review them before investing.
Latest News for SBIO
No articles mention this fund directly in the last 7 days; showing general ETF coverage.
Guided help: AUM is fund size. The expense ratio is the yearly cost baked into returns. NAV is the value of what the fund owns per share; the market price can sit slightly above (premium) or below (discount) it. Total return assumes distributions were reinvested. Every dataset shows its own as-of date because holdings, assets and quotes update on different schedules.